Overview

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free survival (RFS) in AML patients with favorable risk.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Azacitidine
Decitabine